What is it about?
The best therapeutic approach in patients with proliferative glomerulonephritis with monoclonal immunoglobulin deposition (PGMID) is unclear. In an open-label, phase 2 clinical trials, the authors evaluated the safety and efficacy of a 6 month course of intravenous daratumumab at a dose of 16 mg/kg in this population. There were 5 episodes of serious adverse events (2 of which were infection-related). At 12 months all 10 patients with PGNMID who received at least 1 infusion of daratumumab responded to therapy with a significant reduction in proteinuria at 6 months which was sustained in 7 by 12 months.
Featured Image
Photo by Randy Tarampi on Unsplash
Why is it important?
It offers a potential new treatment for this rare disease.
Perspectives
The response was 100%. Very rarely such response can be achieved.
Dr Fernando Fervenza
Mayo College
Read the Original
This page is a summary of: Safety and Efficacy of Daratumumab in Patients with Proliferative GN with Monoclonal Immunoglobulin Deposits, Journal of the American Society of Nephrology, March 2021, American Society of Nephrology,
DOI: 10.1681/asn.2020101541.
You can read the full text:
Resources
Contributors
The following have contributed to this page
